Therefore, rapamycin and several of its derivatives that target the mTOR pathway, such as temsirolimus (CCI-77), everolimus (RAD001) and ridaforolimus (AP23573), have been developed as potential targeted therapeutic agents in NSCLC [37, 39-44]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.